Grace A. Heavey

Grace A. Heavey

Auto-generated profile, based on publicly available information

Grace A. Heavey

Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
CPCloud P. Paweletz
Cloud P. Paweletz
GHGrace A. Heavey
Grace A. Heavey
YKYanan Kuang
Yanan Kuang
EDEmily Durlacher
Emily Durlacher
TKThian Kheoh
Thian Kheoh
PJPasi Antero Jänne
Pasi Antero Jänne
Purpose: Non-invasive monitoring of circulating tumor DNA (ctDNA) has the potential to be a readily available measure for early prediction of clinical response. Here, we report on early ctDNA changes of KRAS G12C in a Phase 2 trial of adagrasib in patients with advanced, KRAS G12C-mutant lung cancer. Experimental Design: We performed serial droplet digital PCR (ddPCR) and plasma NGS on 60 KRAS G12C-mutant patients with lung cancer that participated in cohort A of the KRYSTAL-1 clinical trial. We analyzed the change in ctDNA at 2 specific intervals: Between cycles 1 and 2 and at cycle 4. Changes in ctDNA were compared with clinical and radiographic response. Results: We found that, in general, a maximal response in KRAS G12C ctDNA levels could be observed during the initial approximately 3-week treatment period, well before the first scan at approximately 6 weeks. 35 patients (89.7%) exhibited a decrease in KRAS G12C cfDNA >90% and 33 patients (84.6%) achieved complete clearance by cycle 2. Patients with complete ctDNA clearance at cycle 2 showed an improved objective response rate (ORR) compared with patients with incomplete ctDNA clearance (60.6% vs. 33.3%). Furthermore, complete ctDNA clearance at cycle 4 was associated with an improved overall survival (14.7 vs. 5.4 months) and progression-free survival (HR, 0.3). Conclusions: These results support using early plasma response of KRAS G12C assessed at approximately 3 weeks to anticipate the likelihood of a favorable objective clinical response.

25 November 2025
Verified
Other
Open access
CPCloud P. Paweletz
Cloud P. Paweletz
GHGrace A. Heavey
Grace A. Heavey
YKYanan Kuang
Yanan Kuang
EDEmily Durlacher
Emily Durlacher
TKThian Kheoh
Thian Kheoh
PJPasi Antero Jänne
Pasi Antero Jänne
Supplemental Figure 2: Baseline AF% vs sum of diameter (SOD) at baseline.

1 November 2025 in JCO Precision Oncology
Verified
Journal Article
Closed access
CPCloud P. Paweletz
Cloud P. Paweletz
TFThomas D. Forbes
Thomas D. Forbes
LYLaura Yee
Laura Yee
GHGrace Heavey
Grace Heavey
HHHua-Jun He
Hua-Jun He
CKChris Karlovich
Chris Karlovich
PURPOSE: We previously developed quality control materials (QCMs) to aid in the development of circulating tumor DNA (ctDNA) assays. In this study, we further characterize the performance of the QCMs relative to clinical samples. METHODS: QCMs were provided by three manufacturers. To functionally characterize the QCMs, we (1) evaluated EGFR L858R and ex19del (range, 0.5%-5.0% variant allele frequency [VAF]) in QCMs compared with clinical samples by droplet digital polymerase chain reaction (ddPCR), targeted-amplicon sequencing (Tag-seq), and hybrid capture next-generation sequencing (NGS); and (2) evaluated the QCMs and clinical samples near the Tag-seq limit of detection. A clinical pilot was also conducted in 11 clinical laboratories spanning four continents. RESULTS: For functional characterization, part 1, QCM VAFs for hybrid capture were similar to ddPCR for EGFR L858R but lower for ex19del. By contrast, hybrid capture results for EGFR L858R clinical samples showed a positive trend compared with ddPCR. For amplicon NGS, QCMs performed similarly to clinical samples for both variants. For part 2, observed hit rates approximated expected values. In the clinical pilot, median ex19del VAF was higher for Tag-seq than hybrid capture for both 1.0% and 0.5% QCM formulations. Median QCM L858R VAFs were similar for Tag-seq and hybrid capture, with greatest interlaboratory differences observed for Thermo Fisher Scientific QCMs. For non- EGFR variants, we observed assay and QCM-dependent trends, with no particular QCM or assay driving these trends. CONCLUSION: This project revealed unexpected differences in performance of both assays and QCMs. These findings highlight the need for further validation across diverse alteration types and merit consideration by laboratories that rely on QCMs to develop and perform ctDNA assays for diagnostic applications.

15 August 2023
Verified
Other
Open access
PDF file
CPCloud P. Paweletz
Cloud P. Paweletz
GHGrace A. Heavey
Grace A. Heavey
YKYanan Kuang
Yanan Kuang
EDEmily Durlacher
Emily Durlacher
TKThian Kheoh
Thian Kheoh
PJPasi Antero Jänne
Pasi Antero Jänne
Supplemental Figure 2: Baseline AF% vs sum of diameter (SOD) at baseline.


15 August 2023
Verified
Other
Open access
CPCloud P. Paweletz
Cloud P. Paweletz
GHGrace A. Heavey
Grace A. Heavey
YKYanan Kuang
Yanan Kuang
EDEmily Durlacher
Emily Durlacher
TKThian Kheoh
Thian Kheoh
PJPasi Antero Jänne
Pasi Antero Jänne
Data from Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients